Erasmus Medical Center, Rotterdam partners with Olink to deepen understanding of disease progression and accelerate development of new therapies

0

Olink Proteomics AB

UPPSALA, Sweden, June 16, 2022 (GLOBE NEWSWIRE) — Olink Holding AB (publ) (Nasdaq: OLK) today announced that the Human Genomics Facility at Erasmus Medical Center Rotterdam has adopted Olink technology, becoming the first Olink® Explore a certified laboratory in the Netherlands.

The Rotterdam Human Genomics Facility (HuGe-F) houses one of the largest high-throughput genomics facilities in Europe, offering genomics services to global clients. This partnership offers a new opportunity to combine multiple layers of multi-omics approaches to unravel the mechanisms of human disease biology and accelerate the development of novel therapies.

“In collaboration with the Erasmus MC proteomics platform, HuGe-F now offers a full range of possibilities for measuring proteins in all types of tissues. In the field of population genomics, we see growing interest in measuring large amounts of protein in cohorts around the world. The robust and sensitive Olink technology opens new opportunities to identify the biological mechanisms underlying disease, especially when combined with other layers of genomic information such as genetic variation,” said Joyce van Meurs, Professor of Population Genomics, Head of the Human Genomics Facility at the Erasmus Medical Center, Rotterdam.

Olink® Explore will be used across a wide range of therapeutic areas to advance current understanding of the molecular pathways involved in disease development, progression and outcome. The combination of large-scale genomics and proteomics will facilitate precision medicine efforts by supplementing the knowledge base of complex disease pathophysiological mechanisms, therapeutic targets, and biomarkers associated with drug targets.

“In our department, we aim to unravel the complex immunological and metabolic pathways that play a role in chronic inflammation and infection. In one of our latest studies, the 2000HIV Human Functional Genomics Partnership Program, we are including multiple layers of data to identify factors underlying immune dysregulation in people living with HIV,” said Professor Leo Joosten, IDepartment of Internal Medicine, Radboud UMC, Nijmegen. “Measuring proteomics using the Olink® The Explore 3072 platform is an important part of it. Have a local opportunity to analyze our samples on the Olink® The Explore 3072 platform is very valuable. This allows us to identify circulating biomarkers and pathways related to common non-AIDS comorbidities such as cardiovascular disease and non-alcoholic fatty liver disease, as well as the size and composition of the HIV reservoir.

“This new partnership demonstrates greater democratization of Olink technology and facilitates important work like that of Professor Leo Joosten to lead Olink.® Explore3072 on its full HIV cohort. It is also very much in line with our mission to help the scientific community achieve its goals to better understand the origin of disease, enable earlier and more accurate diagnoses, and enable more efficient and safer drug development. These efforts can fundamentally accelerate the impact of high-specificity proteomics on human health,” said Henk Mouthaan, Vice President Sales and Marketing EMEA, Olink Proteomics.

Contact Investor
Jan Medina, CFA
Vice President Investor Relations and Capital Markets
Mobile: +1 617 802 4157
[email protected]

Media Contact
Andrea Prander
Corporate Communications Manager
Mobile: +46 768 775 275
email:[email protected]

About Olink
Olink Holding AB (Nasdaq:OLK) is a company dedicated to accelerating proteomics in collaboration with the scientific community, in multiple disease areas, to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services that are deployed across leading pharmaceutical companies and leading clinical and academic institutions to deepen understanding of human biology in real time and drive 21st century healthcare through science. actionable and impactful. The company was founded in 2016 and is well established in Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.

About the Human Genomics Platform (HuGe-F)
The Population Genomics Laboratory of the Department of Internal Medicine at Erasmus MC, the largest university hospital in the Netherlands, houses one of the largest high-throughput genomics facilities in Europe. It has been active for 20 years, has processed millions of samples and enables the application of the most advanced genomic technologies to client research projects both inside and outside the Netherlands. Additionally, HuGe-F offers support with study design and data analysis, including data storage. HuGe-F is closely linked to the Population Genomics Laboratory, which focuses on research in the area of ​​genetics and genomics of complex traits and common diseases. HuGe-F is a certified laboratory and works for academic, commercial and clinical clients.

Forward-looking statements
This release may contain forward-looking statements within the meaning of applicable securities laws, including the United States Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding strategy, business plans and direction of Olink. The words “may”, “will”, “could”, “should”, “should”, “expect”, “plan”, “anticipate”, “intend”, “believe”, ” estimate”, “predict”, “project”, “potential”, “continuing”, “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. All forward-looking statements contained in this press release are based on management’s current expectations and beliefs as of the date hereof and are subject to a number of important risks, uncertainties and factors that may cause actual events or results differ materially from those expressed or implied. by any forward-looking statements contained in this press release, including, without limitation, those relating to Olink’s business, operations, supply chain, strategy, objectives and anticipated timelines, including including for the delivery of Olink Explore 3072 and the expansion of the Explore platform, competition and other risks identified in the section titled “Risk Factors” in Olink’s registration statement on Form F- 1, as amended (File No. 333-253818) filed with the United States Securities and Exchange Commission (SEC) and in the other filings, reports and documents that Olink files from time to time with the SEC. Olink expressly disclaims any obligation to update any forward-looking statements contained in this release to reflect any change in its expectations with respect thereto or any change in events, conditions or circumstances on which such statement is based, except as required by law or regulations require it.

Share.

Comments are closed.